| Vipul Vinod Jain, MD | |
|
2335 E Kashian Ln Ste 260, Fresno, CA 93701-2234 | |
| (559) 256-5130 | |
| (559) 485-4504 |
| Full Name | Vipul Vinod Jain |
|---|---|
| Gender | Male |
| Speciality | Pulmonary Disease |
| Experience | 27 Years |
| Location | 2335 E Kashian Ln Ste 260, Fresno, California |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1295927911 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RC0200X | Internal Medicine - Critical Care Medicine | A88214 (California) | Secondary |
| 207RP1001X | Internal Medicine - Pulmonary Disease | A88214 (California) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Community Regional Medical Center | Fresno, CA | Hospital |
| Clovis Community Medical Center | Clovis, CA | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| University Faculty Associates Inc | 6507181708 | 257 |
News Archive
Mpex Pharmaceuticals, Inc. today announced positive data from its Phase 2b clinical trial with Aeroquin((R)) (a novel aerosol formulation of levofloxacin, MP-376) in cystic fibrosis (CF). Trial results showed that nebulized Aeroquin met the primary endpoint of reducing bacterial counts of Pseudomonas aeruginosa (P. aeruginosa) in sputum after 28 days of dosing versus placebo.
Scientists from the Barbara Ann Karmanos Cancer Institute in Detroit will present data that suggests low levels of pre-treatment radiation mimicking the doses delivered by CT scans for image guidance pose no risk to the efficacy of radiotherapy in patients with prostate carcinoma and non-small cell lung carcinoma. The findings will be formally announced on Sunday, Oct. 31, during the American Society of Therapeutic Radiology and Oncology (ASTRO) Annual Meeting.
Writing in the Global Health Governance Blog, Yanzhong Huang, a senior fellow for global health at the Council on Foreign Relations, addresses President Obama about "the challenge of building a mature and mutually beneficial bilateral relationship" with China.
Endo Pharmaceuticals Holdings Inc. today announced a private offering of $400 million aggregate principal amount of senior unsecured notes due 2020, subject to market conditions. The notes will be unsecured, unsubordinated obligations of the Company and will be guaranteed by certain of the Company's domestic subsidiaries.
Biologists at New York University have discovered a system by which a random choice between two distinct cellular fates in the fruit fly eye becomes firmly established.
› Verified 7 days ago
| Entity Name | Fresno Community Hospital And Medical Center |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1710151881 PECOS PAC ID: 3173430865 Enrollment ID: O20050531000251 |
News Archive
Mpex Pharmaceuticals, Inc. today announced positive data from its Phase 2b clinical trial with Aeroquin((R)) (a novel aerosol formulation of levofloxacin, MP-376) in cystic fibrosis (CF). Trial results showed that nebulized Aeroquin met the primary endpoint of reducing bacterial counts of Pseudomonas aeruginosa (P. aeruginosa) in sputum after 28 days of dosing versus placebo.
Scientists from the Barbara Ann Karmanos Cancer Institute in Detroit will present data that suggests low levels of pre-treatment radiation mimicking the doses delivered by CT scans for image guidance pose no risk to the efficacy of radiotherapy in patients with prostate carcinoma and non-small cell lung carcinoma. The findings will be formally announced on Sunday, Oct. 31, during the American Society of Therapeutic Radiology and Oncology (ASTRO) Annual Meeting.
Writing in the Global Health Governance Blog, Yanzhong Huang, a senior fellow for global health at the Council on Foreign Relations, addresses President Obama about "the challenge of building a mature and mutually beneficial bilateral relationship" with China.
Endo Pharmaceuticals Holdings Inc. today announced a private offering of $400 million aggregate principal amount of senior unsecured notes due 2020, subject to market conditions. The notes will be unsecured, unsubordinated obligations of the Company and will be guaranteed by certain of the Company's domestic subsidiaries.
Biologists at New York University have discovered a system by which a random choice between two distinct cellular fates in the fruit fly eye becomes firmly established.
› Verified 7 days ago
| Entity Name | University Faculty Associates Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1073911137 PECOS PAC ID: 6507181708 Enrollment ID: O20150211000164 |
News Archive
Mpex Pharmaceuticals, Inc. today announced positive data from its Phase 2b clinical trial with Aeroquin((R)) (a novel aerosol formulation of levofloxacin, MP-376) in cystic fibrosis (CF). Trial results showed that nebulized Aeroquin met the primary endpoint of reducing bacterial counts of Pseudomonas aeruginosa (P. aeruginosa) in sputum after 28 days of dosing versus placebo.
Scientists from the Barbara Ann Karmanos Cancer Institute in Detroit will present data that suggests low levels of pre-treatment radiation mimicking the doses delivered by CT scans for image guidance pose no risk to the efficacy of radiotherapy in patients with prostate carcinoma and non-small cell lung carcinoma. The findings will be formally announced on Sunday, Oct. 31, during the American Society of Therapeutic Radiology and Oncology (ASTRO) Annual Meeting.
Writing in the Global Health Governance Blog, Yanzhong Huang, a senior fellow for global health at the Council on Foreign Relations, addresses President Obama about "the challenge of building a mature and mutually beneficial bilateral relationship" with China.
Endo Pharmaceuticals Holdings Inc. today announced a private offering of $400 million aggregate principal amount of senior unsecured notes due 2020, subject to market conditions. The notes will be unsecured, unsubordinated obligations of the Company and will be guaranteed by certain of the Company's domestic subsidiaries.
Biologists at New York University have discovered a system by which a random choice between two distinct cellular fates in the fruit fly eye becomes firmly established.
› Verified 7 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Vipul Vinod Jain, MD 2625 E Divisadero St, Fresno, CA 93721-1431 Ph: (559) 443-2682 | Vipul Vinod Jain, MD 2335 E Kashian Ln Ste 260, Fresno, CA 93701-2234 Ph: (559) 256-5130 |
News Archive
Mpex Pharmaceuticals, Inc. today announced positive data from its Phase 2b clinical trial with Aeroquin((R)) (a novel aerosol formulation of levofloxacin, MP-376) in cystic fibrosis (CF). Trial results showed that nebulized Aeroquin met the primary endpoint of reducing bacterial counts of Pseudomonas aeruginosa (P. aeruginosa) in sputum after 28 days of dosing versus placebo.
Scientists from the Barbara Ann Karmanos Cancer Institute in Detroit will present data that suggests low levels of pre-treatment radiation mimicking the doses delivered by CT scans for image guidance pose no risk to the efficacy of radiotherapy in patients with prostate carcinoma and non-small cell lung carcinoma. The findings will be formally announced on Sunday, Oct. 31, during the American Society of Therapeutic Radiology and Oncology (ASTRO) Annual Meeting.
Writing in the Global Health Governance Blog, Yanzhong Huang, a senior fellow for global health at the Council on Foreign Relations, addresses President Obama about "the challenge of building a mature and mutually beneficial bilateral relationship" with China.
Endo Pharmaceuticals Holdings Inc. today announced a private offering of $400 million aggregate principal amount of senior unsecured notes due 2020, subject to market conditions. The notes will be unsecured, unsubordinated obligations of the Company and will be guaranteed by certain of the Company's domestic subsidiaries.
Biologists at New York University have discovered a system by which a random choice between two distinct cellular fates in the fruit fly eye becomes firmly established.
› Verified 7 days ago
Maulik Shah, MD Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 7300 N Fresno St, Fresno, CA 93720 Phone: 559-448-4555 | |
Rami Alrezk, MD Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 155 N Fresno St, Fresno, CA 93701 Phone: 559-499-6479 | |
Dr. John R Nelson, MD Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 7061 N Whitney, Suite 101, Fresno, CA 93720 Phone: 559-299-0224 Fax: 559-299-4201 | |
Dexter T Estrada, M.D. Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 7130 N Millbrook Ave Ste 100, Fresno, CA 93720 Phone: 559-326-1222 Fax: 559-326-1230 | |
Dr. Sherry Lopez, D.O. Pulmonary Disease Medicare: Medicare Enrolled Practice Location: 3209 W Shaw Ave, Suite 114, Fresno, CA 93711 Phone: 559-224-4977 Fax: 559-224-4980 | |
Maria Flordeliz Arambulo, MD Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 2823 Fresno St, Fresno, CA 93721 Phone: 559-499-6484 Fax: 559-499-6501 | |
Shreela Mishra, Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 7085 N Chestnut Ave Ste 101, Fresno, CA 93720 Phone: 559-323-9236 Fax: 559-323-0294 |